The relevance of iron in the pathogenesis of Parkinson's disease

被引:233
作者
Götz, ME
Double, K
Gerlach, M
Youdim, MBH
Riederer, P
机构
[1] Univ Wurzburg, Dept Pharmacol & Toxicol, Wurzburg, Germany
[2] Prince Wales Med Res Inst, Sydney, NSW, Australia
[3] Univ Wurzburg, Dept Child & Youth Psychiat & Psychotherapy, Wurzburg, Germany
[4] Eve Topf & Natl Parkinson Fdn, Ctr Excellence Neurodegenerat Dis Res, Haifa, Israel
[5] Tech Fac Med, Dept Pharmacol, Haifa, Israel
[6] Univ Wurzburg, Dept Psychiat, D-8700 Wurzburg, Germany
来源
REDOX-ACTIVE METALS IN NEUROLOGICAL DISORDERS | 2004年 / 1012卷
关键词
Parkinson's disease; substantia nigra; dopamine; iron; transition metal; neuromelanin; alpha-synuclein; Lewy body; oxidative stress; radicals;
D O I
10.1196/annals.1306.017
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Investigations that revealed increased levels of iron in postmortem brains from patients with Parkinson's disease (PD) as compared to those from individuals not suffering from neurological disorders are reported. The chemical natures in which iron predominates in the brain and the relevance of neuromelanin for neuronal iron binding are discussed. Major findings have been that iron levels increase with the severity of neuropathological changes in PD, presumably due to increased transport through the blood-brain barrier in late stages of parkinsonism. Glial iron is mainly stored as ferric iron in ferritin, while neuronal iron is predominantly bound to neuromelanin. Iron overload may induce progressive degeneration of nigrostriatal neurons by facilitating the formation of reactive biological intermediates, including reactive oxygen species, and the formation of cytotoxic protein aggregates. There are indications that iron-mediated neuronal death in PD proceeds retrogradely. These results are also discussed with respect to their relevance for disease progression in relation to cytotoxic alpha-synuclein protofibril formation.
引用
收藏
页码:193 / 208
页数:16
相关论文
共 132 条
[1]  
Aime S, 2000, MOVEMENT DISORD, V15, P977, DOI 10.1002/1531-8257(200009)15:5<977::AID-MDS1032>3.0.CO
[2]  
2-Q
[3]   MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects [J].
Bartzokis, G ;
Cummings, JL ;
Markham, CH ;
Marmarelis, PZ ;
Treciokas, LJ ;
Tishler, TA ;
Marder, SR ;
Mintz, J .
MAGNETIC RESONANCE IMAGING, 1999, 17 (02) :213-222
[4]   DEGENERATION OF SUBSTANTIA-NIGRA IN CHRONIC PARKINSONS-DISEASE VISUALIZED BY TRANSCRANIAL COLOR-CODED REAL-TIME SONOGRAPHY [J].
BECKER, G ;
SEUFERT, J ;
BOGDAHN, U ;
REICHMANN, H ;
REINERS, K .
NEUROLOGY, 1995, 45 (01) :182-184
[5]   Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats [J].
Ben Shachar, D ;
Kahana, N ;
Kampel, V ;
Warshawsky, A ;
Youdim, MBH .
NEUROPHARMACOLOGY, 2004, 46 (02) :254-263
[6]   THE IRON CHELATOR DESFERRIOXAMINE (DESFERAL) RETARDS 6-HYDROXYDOPAMINE-INDUCED DEGENERATION OF NIGROSTRIATAL DOPAMINE NEURONS [J].
BENSHACHAR, D ;
ESHEL, G ;
FINBERG, JPM ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1991, 56 (04) :1441-1444
[7]   IRON MELANIN INTERACTION AND LIPID-PEROXIDATION - IMPLICATIONS FOR PARKINSONS-DISEASE [J].
BENSHACHAR, D ;
RIEDERER, P ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1991, 57 (05) :1609-1614
[8]   INTRANIGRAL IRON INJECTION INDUCES BEHAVIORAL AND BIOCHEMICAL PARKINSONISM IN RATS [J].
BENSHACHAR, D ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1991, 57 (06) :2133-2135
[9]   Echogenicity of the substantia nigra -: Association with increased iron content and marker for susceptibility to nigrostriatal injury [J].
Berg, D ;
Roggendorf, W ;
Schröder, U ;
Klein, R ;
Tatschner, T ;
Benz, P ;
Tucha, O ;
Preier, M ;
Lange, KW ;
Reiners, K ;
Gerlach, M ;
Becker, G .
ARCHIVES OF NEUROLOGY, 2002, 59 (06) :999-1005
[10]   Relationship of substantia nigra echogenicity and motor function in elderly subjects [J].
Berg, D ;
Siefker, C ;
Ruprecht-Dörfler, P ;
Becker, G .
NEUROLOGY, 2001, 56 (01) :13-17